



***Corresponding author:** George Fenton, School of Pharmaceutical Science,
University of California, USA, E-mail: georgefenton@uc.ac.ca

informing strategies to safeguard vulnerable populations from the adverse consequences of combined exposures.

References

1. Srikanth M, Kessler JA (2012) Nanotechnology novel therapeutics for CNS disorders. *Nat Rev Neurol* 8: 307.
2. Vijayan M, Reddy PH (2016) Stroke, vascular dementia, and Alzheimer's disease: molecular links. *J Alzheimer Dis* 54: 427-443.
3. Kabanov A, Gendelman H (2007) Nanomedicine in the diagnosis and therapy of neurodegenerative disorders. *Prog Polym Sci* 32: 1054-1082.
4. Nazem A, Mansoori GA (2008) Nanotechnology solutions for Alzheimer's disease: advances in research tools, diagnostic methods and therapeutic agents. *J Alzheimer Dis* 13: 199-223.
5. Flachenecker P (2006) Epidemiology of neuro-immunological diseases. *J Neurol* 253: 2-8.
6. Fonseca-Santos B, Gremião MP, Chorilli M (2012) Nanotechnology-based drug barrier. *Adv Drug Deliv Rev* 64: 640-665.
7. Ueno M (2010) Transporters in the brain endothelial barrier. *Curr Med Chem* 17: 1125-1138.
8. Fillebeen F (1999) Receptor-mediated transcytosis of lactoferrin through the blood-brain barrier. *J Biol Chem* 274: 7011-7017.
9. Roney C (2005) Targeted nanoparticles for drug delivery through the blood-brain barrier for Alzheimer's disease. *J Control Release* 108: 193-214.
10. Lu CT (2014) Current approaches to enhance CNS delivery of drugs across the brain barriers. *Int J Nanomed* 9: 2241.
11. Athira S, N Prajitha, P. Mohanan (2018) Interaction of Nanoparticles with Central Nervous System and Its Consequences.